-
Medlab was born June 2012.
Designed to research and develop new biological medicines, specifically targeting health conditions previously thought to be untreatable with biologics
September 2012
Work starts on Medlab’s new laboratories – capable of performing state of the art biological and blood research as well as quality, clinical and medical testing, and pathology work
October 2012
Professor Luis Vitetta joins as Director of Medical Research
-
April 2013
Our purpose built laboratories gain Physical Containment Level 2 (PC2) certification
August 2013
5 provisional patents are filed representing our first projects in biological medicine development in the areas of:
- Pain and pain management
- Obesity
- Chronic kidney disease
- Depression
- Anti-ageing and telomere activity
September 2013
First Australian patent granted: Liquid compositions comprising Vitamin D and uses thereof
-
Medlab Research facilities upgraded for research using illicit drugs and research and pharmaceutical development
Medlab launches
Its first 3 evidence-based nutraceuticals:
- MultiBiotic
- NRGBiotic
- Enbiotic
-
July 2015
Medlab is listed on the Australian Stock Exchange ASX:MDC
July 2015
Granted a Cannabis Research Deed, making Medlab the first commercial entity in Australia to be given such a licence
December 2015
Medlab completes first US export order and signs first Chinese distribution agreement for Nutraceuticals
Medlab launches
Its first two (2) NanoCelle® nutraceuticals:
- NanoCelle® D3
- NanoCelle® B12
And launches an additional seven (7) specific evidence-based nutraceuticals
Trial:
Phase 1 Study for Nutraceuticals concludes for Pre-Diabetes and T2DM. Showing significant gut microbiome changes achievable with secondary benefits such as reduction in glucose markers on new Medlab product
8 Patents granted:
- Probiotic compositions and uses thereof:
- for treatment of obesity-related disorders – Non-alcoholic fatty liver disease (NAFLD)
- NRGBiotic
- (VI) ImmuneBiotic
- EnBiotic
- NRGBiotic (Innovation)
- (II) – Cannabinoids
- (I) – Chronic kidney disease (CKD)
- Treatment for depression and depressive disorders – Orotate
-
March 2016
US corporate name change from InMed to Medlab
August 2016
Medlab signs Aphria Agreement for cannabis supply on proprietary blend
November 2016
TGA grants licence for Cannabis (Import licence)
Medlab launches
New NanoCelle™ product: NanoCelle™ Activated B12
And 7 new evidenced based nutraceuticals
Trials:
- Phase 2a Depression Study using NRG Biotic, announced and commenced
- Phase I NRGBiotic™ / Depression Trial completed
4 patents granted:
- Probiotic compositions:
- for weight management - W8Biotic
- for rehydration – ORSBiotic
- Transmucosal and transdermal delivery systems – NanoCelle
- Yeast-containing compositions for gastrointestinal health - GastroDaily
-
March 2017
Channel 9 coverage on Medlab's NanoCelle® Atorvastatin
June 2017
Medlab signs agreement with Singapore for nutraceutical distribution
November 2017
TGA Special Access Scheme (SAS) allows use of Cannabis medicines
Trials:
- Phase II NRGBiotic™ / Depression trial begins with ethics granted
Medlab receives HREC approval for two cannabis studies:
- NanaBis™
- NanaBidial™
Patent granted
- NRGBiotic™ (anti-depression)
-
December 2018
Medlab expands into Europe
Trials:
- NanaBis™ advanced cancer pain Trial at Royal North Shore Hospital commences
- Phase II NRGBiotic™/Depression Trial recruitment begins
- Successful completion of phase I NanaBis™ Trial
-
Nutraceuticals introduced to 2100 pharmacies
Trials:
- NanaBis™ Trial II Ethics approval
- NanaBidial™ Phase I trial complete
-
Australian patent granted:
- NanoCelle®
Trials:
- UK NanaBis™ trial launch
-
July 2021
Master Services Agreement (MSA) in UK
Patents granted:
- NanoCelle® – Europe & Canada
Trials:
- Synthetic introduction to phase III NanaBis™ announced
- NanaBis™ Phase III Trials approved in Australia
- Strong NRGBiotic™ results achieved
11-13 LORD ST, BOTANY
BUILDING A, UNIT A5 – A6, BOTANY QUARTER
NSW, 2019, AUSTRALIA
www.medlab.co
OFFICE HOURS: 8:30AM - 5PM EST
AUS: 1300 369 570
AUS: +61 2 8188 0311
USA: +1 947 771 8119
UK: +44 20 8138 0311
FAX: +61 2 9699 3347
Email: hello@medlab.co